Effect of coenzyme Q10 on warfarin hydroxylation in rat and human liver microsomes

Our previous animal study has suggested that the accelerated metabolism of warfarin enantiomers with concurrent coenzyme Q(10) (CoQ(10)) treatment accounts for the reduced anticoagulant effect of warfarin in rats. The present study was to assess the effect of CoQ(310) on individual hydroxylation pathways of the in vitro microsomal metabolism of warfarin enantiomers and to extrapolate in vitro data to in vivo situation. The effect of the antioxidant CoQ(10) on the hydroxylation of warfarin enantiomers was examined using rat and human liver microsomes. Based on the in vitro kinetic data, together with the information retrieved from the literature, the magnitude of warfarin-CoQ(10) interaction in man was quantitatively predicted. In rat liver microsomes, CoQ(10) exhibited a selective activation effect on the 4'-hydroxylation of S-warfarin, with a K(A) value (i.e. dissociation constant of the enzyme-activator complex) being one third and one fifth of those for the 6- and 7-hydroxylation, respectively. The activation effect of CoQ(10) was selective towards the 6- and 7-hydroxylation of R-warfarin at low substrate concentrations, but towards the 4'-hydoxylation of the R-enantiomer at high substrate concentrations. In human liver microsomes, CoQ(10) was a selective activator of the 7-hydroxylation of both R- and S-enantiomers of warfarin, with K(A) values being half to one twelfth of those for the other pathways. A relatively accurate prediction was made for the increase in the total and hepatic clearance of both S- and R-warfarin in rats with concurrent CoQ(10) treatment based on their respective overall hydroxylation, when the active transport of CoQ(10)into the hepatocytes was taken into consideration. In man, one would expect about 32% and 17% increase in the total clearance of S- and R-warfarin, respectively, with coadministration of 100 mg CoQ(10). In both species, CoQ(10) had enzyme activation effect, which appeared to be regioselective but not stereoselective, on the formation of the phenolic metabolites of warfarin enantiomers. A moderate increase in the total clearance of warfarin enantiomers could occur with coadministration of CoQ(10)in humans.     

Stabilization and induction of a lipid peroxidation inhibitor present in the soluble fraction of rat liver homogenates

An inhibitor of lipid peroxidation present in the soluble fraction of rat liver homogenates has been stabilized by dithiothreitol. In the presence of an appropriate concentration of dithiothreitol, soluble fractions from 3-methylcholanthrene-pretreated rats and from older rats exhibited stronger inhibition of lipid peroxidation than those from control rats.     

Regiochemistry and substrate stereoselectivity of O-demethylation of verapamil in the presence of the microsomal fraction from rat and human liver

The oxidative O-demethylation of verapamil (1), a calcium channel antagonist, in the presence of rat and human liver microsomes was examined. By using GC/MS methodology and synthesized regioisomeric standards, we showed that three of the four possible monophenolic metabolites, alpha-[3-([2-(3,4-dimethoxyphenyl)ethyl]methyl-amino) propyl]-3-methoxy-4-hydroxy-alpha-(1-methylethyl)phenyl-acetonitrile (2), alpha-[3-([2-(3,4-methoxyphenyl)ethyl]methyl-amino) propyl]-3-hydroxy-4-methoxy-alpha-(1-methylethyl)phenylaceto nitrile (3), and alpha-[3-([2-(3-methoxy-4-hydroxyphenyl)ethyl]methylamino) propyl]-3,4-dimethoxy-alpha-(1-methylethyl)phenylacetonitrile (4) were formed. The other possible regioisomeric monophenolic metabolite 5 was not observed. Substrate stereoselectivity for the O-demethylation process was determined when pseudoracemic verapamil [equimolar (S)-(-)-verapamil-d6 and (R)-(+)-verapamil-d0] was used as substrate. In the presence of rat liver microsomes, significant substrate stereoselectivity was observed for formation of 4 (S/R ratio 2.28), whereas marginal substrate stereoselectivity was observed in the formation of both 3 and 2 (S/R ratio approximately 0.8). Substrate stereoselectivity for the O-demethylation process in the presence of human liver microsomes was slight and variable (six samples). Quantitatively, the ratio of O-demethylation products obtained (4:2:3) was similar in the presence of rat and human liver microsomes. In both systems, more than one-half of the total O-demethylation occurred in the aromatic ring of the phenethylamine moiety, and of the total O-demethylation process, more para- than meta-O-demethylation was observed. The similarity of regioselectivity for O-demethylation in the presence of rat and human liver microsomes suggests a similar cytochrome P-450 isozyme or set of isozymes may be responsible for the O-demethylation process.     

Reductive metabolism of metyrapone by a quercitrin-sensitive ketone reductase in mouse liver cytosol

Mouse liver cytosol catalyses the reduction of metyrapone to the corresponding alcohol metabolite metyrapol. The enzyme involved was characterized as a NADPH-dependent carbonyl reductase which is strongly inhibited by the plant flavonoid quercitrin but which shows no sensitivity to phenobarbital. Thus, by inhibitor subdivision of carbonyl reductases the metyrapone reductase in mouse liver cytosol has to be classified as a ketone reductase rather than an aldehyde reductase, as it was shown previously for the analogous enzyme in mouse liver microsomes based on the same pattern of inhibitor classification. Moreover, immunological comparison of the metyrapone reductases from the two subcellular fractions reveal no common antigenic determinants indicating the structural difference between these enzymes. In conclusion, metyrapone undergoes reductive biotransformation mediated by two clearly distinct carbonyl reductases located in different subcellular compartments of mouse liver cells. Considering the convenient and sensitive HPLC-method for direct metyrapol determination, metyrapone may serve as a useful tool in the investigation of these enzymes, although their physiological roles remain to be determined.     

Differential hormonal regulation of carbonyl reductase activities in liver and kidney microsomes of rat

1. In the male rat, hepatic microsomal carbonyl reductase (CR) activity decreased by testectomy (Tx) was restored to the control level by the treatment with testosterone propionate (TP), even though the enzyme activity decreased by hypophysectomy (Hx) was not increased by the treatment with TP. On the other hand, renal microsomal CR activities decreased by Tx and Hx were markedly increased by the treatment with TP. 2. The treatment with TP had no effect on the CR activity in liver microsomes of the ovariectomized or hypophysectomized female rat. On the other hand, the CR activities in kidney microsomes of the ovariectomized and hypophysectomized female rat were significantly increased by the treatment with TP. 3. The results indicate that in rat programmed by neonatal androgens, the hepatic microsomal CR activity is regulated indirectly by androgens through the hypothalamus-pituitary system, whereas the hormonal regulation of the renal microsomal CR activity is not via the pituitary. We conclude that the regulatory mechanism of the CR activity in liver microsomes is distinguishable from that in kidney microsomes.     

Differential hormonal regulation of carbonyl reductase activities in liver and kidney microsomes of rat

1. In the male rat, hepatic microsomal carbonyl reductase (CR) activity decreased by testectomy (Tx) was restored to the control level by the treatment with testosterone propionate (TP), even though the enzyme activity decreased by hypophysectomy (Hx) was not increased by the treatment with TP. On the other hand, renal microsomal CR activities decreased by Tx and Hx were markedly increased by the treatment with TP. 2. The treatment with TP had no effect on the CR activity in liver microsomes of the ovariectomized or hypophysectomized female rat. On the other hand, the CR activities in kidney microsomes of the ovariectomized and hypophysectomized female rat were significantly increased by the treatment with TP. 3. The results indicate that in rat programmed by neonatal androgens, the hepatic microsomal CR activity is regulated indirectly by androgens through the hypothalamus-pituitary system, whereas the hormonal regulation of the renal microsomal CR activity is not via the pituitary. We conclude that the regulatory mechanism of the CR activity in liver microsomes is distinguishable from that in kidney microsomes.     

Inhibition of human aldehyde reductase by drugs for testing the function of liver and kidney.

Drugs for testing the function of liver and kidney (sulfobromophthalein, phenolsulfonphthalein, indigo carmine and indocyanine green) and other organic anions (rose bengal and haematin) were found to potently inhibit human liver aldehyde reductase that is involved in the detoxification of 3-deoxyglucosone and methylglyoxal, reactive intermediates, during the formation of advanced glycation end products. The inhibition patterns by the compounds were non-competitive with respect to both coenzyme (NADPH) and substrate (D-glucuronate). The kinetics of the inhibition by a mixture of the 2 inhibitors suggests that all the inhibitory compounds bind to overlapping sites on the enzyme. The binding of rose bengal, sulfobromophthalein and phenylsulfonphthalein to the free enzyme was detected by ultrafiltration assay. However, in the reverse reaction, the enzyme was inhibited competitively with respect to the alcohol substrate by rose bengal, haematin, phenolsulfonphthalein, sulfobromophthalein, indigo carmine and indocyanine green, which showed Ki values of 0.1, 1, 3, 4, 4 and 10 microM, respectively. The results suggest that these potent inhibitors bind weakly to the free enzyme and tightly to the enzyme-NADP binary complex.     

Studies on rat kidney 15-hydroxy-prostaglandin dehydrogenase.

Rat kidney 15-hydroxy-prostaglandin dehydrogenase (PGDH) was isolated, and its characteristics and the effects of various drugs upon it were examined. The enzyme was found in the cell cytosol; was labile when unfrozen; and most active at alkaline pH, at 41°, and with the E prostaglandins. Additionally, the enzyme was inhibited by furosemide (K_i = 0.019 mM), ethacrynic acid (K_i = 0.27 mM, phenylbutazone (K_i = 0.16 mM), acetylsalicylic acid (K_i = 3.8 mM), and potassium cyanide (K_i = 1.03 mM). Inhibition of PGDH may play a role in the mechanism of action of the diuretic and anti-inflammatory drugs. Little or no inhibition was seen with amobarbital, hydralazine, alpha-methyldopa, bethanidine and guanethidine. Amobarbital inhibits NADH oxidase (K_i = 0.5 mM), but does not inhibit PGDH. This drug, therefore, may be useful in permitting the use of the fluorometric assay for PGDH in preparations of PGDH contaminated by NADH oxidase.     

Aldehyde reductase from rat liver is a 3 alpha-hydroxysteroid dehydrogenase.

Rat liver was previously shown to contain [V.G. Erwin and R.A. Deitrich, Biochem. Pharmacol.21, 2915 (1972)] two aldehyde reductases (EC 1.1.1.2) in addition to alcohol dehydrogenase (EC 1.1.1.1). The present paper demonstrates that one of these aldehyde reductases also catalyzes reversible reduction of 3-ketosteroids of A/B cis configuration. The product of reduction appears to be 3α-alcohol, rather than 3β-alcohol, the product of reduction of the same 3-ketone by rat liver alcohol dehydrogenase. This difference in the steric course of reduction may be useful for distinguishing aldehyde reductase from alcohol dehydrogenase. Since 3α-alcohols of A/B cis configuration are universally distributed in the bile of vertebrates, the steroid activity of aldehyde reductase may be connected with its physiological function.     

Determination of the epigenetic effects of ochratoxin in a human kidney and a rat liver epithelial cell line.

Epidemiological studies have implicated ochratoxin A (OTA), a fungal metabolic-contaminant of animal and human food sources, in Balkan Endemic Nephropathy and renal tumors. Many environmental toxicants operate through nongenotoxic mechanisms that epigenetically control gene expression leading to a diseased state. Gap junctional intercellular communication (GJIC) plays a central role in the epigenetic control of genes in which alteration of normal GJIC has been implicated in many human pathologies, including cancer, teratogenesis, reproductive dysfunction and peripheral neuropathies. The cell proliferative stages of human diseases, such as cancer, also involves the induction of signal transduction pathways controlling the mitogenic steps, in which the mitogen activated protein kinases (MAPK), such as extracellular receptor kinase (ERK) and p38, are central to mitogenesis. We therefore determined the effects of OTA on GJIC and MAPK in a human kidney and rat liver epithelial cell line. OTA reversibly inhibited GJIC at noncytotoxic doses in the rat liver but not the human kidney cell line. Similarly, OTA was also a strong activator of MAPK, ERK and p38, in the rat liver cells but only weakly activated ERK and had no affect on p38 in the human kidney cell line. Another hallmark of human diseases is an abnormal alteration of apoptosis, also known as programmed cell death. We used our myc-transfected cell line, which exhibits higher levels of apoptosis, to test the effects of OTA on apoptosis. OTA greatly induced apoptosis in this cell line, which is contrary to the effects of most tumor promoters. In summary, OTA exhibits tumor promoting properties in the liver, but the effects of OTA on the human kidney epithelial cells suggested a lack of tumorigenic activity assuming that these epithelial cells, like the rat liver epithelial cells, are a primary target for carcinogens. These results also indicate that the nephrotoxicity of OTA either does not involve GJIC, assuming these epithelial cells play a vital role in kidney physiology, or that a more differentiated kidney cell type is the target for OTA toxicity, of which the role of GJIC remains unknown.     

The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase works as an arsenate reductase in human red blood cells and rat liver cytosol.

The mammalian enzymes responsible for reduction of the environmentally prevalent arsenate (AsV) to the much more toxic arsenite (AsIII) are unknown. In the previous paper (Nemeti and Gregus, 2005), we proposed that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and/or phosphoglycerate kinase (PGK) may catalyze reduction of AsV in human red blood cells (RBC), hemolysate, or rat liver cytosol. In testing this hypothesis, we show here that, if supplied with glutathione (GSH), NAD, and glycolytic substrate, the mixture of purified GAPDH and PGK indeed catalyzes the reduction of AsV. Further analysis revealed that GAPDH is endowed with AsV reductase activity, whereas PGK serves as an auxiliary enzyme, when 3-phosphoglycerate is the glycolytic substrate. The GAPDH-catalyzed AsV reduction required GSH, NAD, and glyceraldehyde-3-phosphate. ADP and ATP moderately, whereas NADH strongly inhibited the AsV reductase activity of the enzyme even in the presence of NAD. Koningic acid (KA), a specific and irreversible inhibitor of GAPDH, inhibited both the classical enzymatic and the AsV-reducing activities of the enzyme in a concentration-dependent fashion. To assess the contribution of GAPDH to the reduction of AsV carried out by hemolysate, rat liver cytosol, or intact erythrocytes, we determined the concentration-dependent effect of KA on AsV reduction by these cells and extracts. Inactivation of GAPDH by KA abolished AsV reduction in intact RBC as well as in the hemolysate and the liver cytosol, when GAPDH in the latter extracts was abundantly supplied with exogenous NAD and glycolytic substrate. However, despite complete inactivation of GAPDH by KA, the hepatic cytosol exhibited significant residual AsV-reducing activity in the absence of exogenous NAD and glycolytic substrate, suggesting that besides GAPDH, other cytosolic enzyme(s) may contribute to AsV reduction in the liver. In conclusion, the key glycolytic enzyme GAPDH can fortuitously catalyze the reduction of AsV to AsIII, if GSH, NAD, and glycolytic substrate are available. AsV reduction may take place during, or as a consequence of, the arsenolytic cleavage of the thioester bond formed between the enzyme's Cys149 and the 3-phosphoglyceroyl moiety of the substrate. Although GAPDH is exclusively responsible for reduction of AsV in human erythrocytes, its role in AsV reduction in vivo remains to be determined.     

Triclosan as a substrate and inhibitor of 3'-phosphoadenosine 5'-phosphosulfate-sulfotransferase and UDP-glucuronosyl transferase in human liver fractions.

Triclosan is a broad spectrum antibacterial agent used in many household products. Due to its structural similarity to polychlorobiphenylols, which are potent inhibitors of the sulfonation and glucuronidation of 3-hydroxy-benzo[a]pyrene, it was hypothesized that triclosan would inhibit these phase II enzymes. This study was designed to assess the interactions of triclosan as a substrate and inhibitor of 3'-phosphoadenosine 5'-phosphosulfate-sulfotransferases and UDP-glucuronosyltransferases in human liver cytosol and microsomes. Triclosan was sulfonated and glucuronidated in human liver. The apparent Km and Vmax values for triclosan sulfonation were 8.5 microM and 0.096 nmol/min/mg protein, whereas Km and Vmax values for glucuronidation were 107 microM and 0.739 nmol/min/mg protein. Triclosan inhibited the hepatic cytosolic sulfonation of 3-hydroxybenzo(a)pyrene (3-OH-BaP), bisphenol A, p-nitrophenol, and acetaminophen with IC50 concentrations of 2.87, 2.96, 6.45, and 17.8 microM, respectively. Studies of 3-OH-BaP sulfonation by expressed human SULT1A1*1, SULT1A1*2, SULT1B1, and SULT1E1 showed that triclosan inhibited the activities of each of these purified enzymes with IC50 concentrations between 2.09 and 7.5 microM. Triclosan was generally a less potent inhibitor of microsomal glucuronidation. IC50 concentrations for triclosan with 3-OH-BaP, acetaminophen, and bisphenol A as substrates were 4.55, 297, and >200 microM, respectively. Morphine glucuronidation was not inhibited by 50 microM triclosan. The kinetics of 3-OH-BaP sulfonation and glucuronidation were examined in the presence of varying concentrations of triclosan: the inhibition of sulfonation was noncompetitive, whereas that of glucuronidation was competitive. These findings reveal that the commonly used bactericide triclosan is a selective inhibitor of the glucuronidation and sulfonation of phenolic xenobiotics.     

Enantioselective hydrolysis of lorazepam 3-acetate by esterases in human and rat liver microsomes and rat brain S9 fraction.

Rates of hydrolysis of racemic and enantiomeric lorazepam 3-acetates (LZA) by esterases in human and rat liver microsomes and rat brain S9 fraction were compared. LZA and its hydrolysis product were analyzed by chiral stationary phase HPLC. When rac-LZA was the substrate, the (R)-LZA was hydrolyzed 2.7-fold and 6.8-fold faster than the (S)-LZA by esterases in rat and human liver microsomes, respectively. In contrast, esterases in rat brain S9 fraction were enantioselective toward the (S)-LZA. The specific activities (nmol of LZA hydrolyzed/mg protein/min) of liver microsomes in the hydrolysis of enantiomerically pure (R)-LZA were approximately 210 (rat) and 1330 (human), and in the hydrolysis of enantiomerically pure (S)-LZA were 25 (rat) and 8 (human). The specific activities of rat brain S9 fraction in the hydrolysis of enantiomerically pure (R)-LZA and (S)-LZA were approximately 3 and 6 nmol/mg protein/min, respectively. Results also indicated an enantiomeric interaction in the hydrolysis of rac-LZA; the presence of (R)-LZA stimulated the hydrolysis of (S)-LZA by all esterase preparations, whereas the presence of (S)-LZA stimulated the hydrolysis of (R)-LZA in rat brain S9 fraction and inhibited the hydrolysis of (R)-LZA in rat and human liver microsomes.